Reporter brief
Pharmacokinetics, Safety, and Efficacy of Fisetin - A Phase I and Pilot Phase IIa Study
What happened
Trial registry update: RECRUITING. No results reported in the supplied registry record.
Why it matters
Assessment pending; this report does not establish a change in evidence.
What it does NOT prove
- The abstract reports only planned study design and rationale, not actual findings—no efficacy results, safety outcomes, or pharmacokinetic data are stated. Enrollment and completion numbers are not provided, so it is unclear whether the trial was fully conducted. No evidence of whether fisetin actually reduced senescent cells, inflammation, or improved health in the study participants is presented.
Study design and sample
Rct; Human.
Healthy volunteers and older patients with multiple chronic diseases
- Design
- Rct
- Sample
- —
- Journal
- Ove Andersen
- Published
- May 19, 2026
Effect size
Not recorded.
Caveats
- Assessment: Unassessed.
- Only the source material recorded on this evidence page was assessed.
Conflicts and funding
Not recorded.
Previous evidence
See the Senolytics timeline and recorded assessment for prior evidence.
Primary source
Cancel Death charts and briefs may be reproduced editorially with attribution to CancelDeath.com. This brief is generated from the primary recorded source facts and assessment. Its review status is shown below; verify quotations against the paper before publication.